Результати застосування бактерій роду Bacillus spp. у вигляді спрея в лікуванні гострого вірусного тонзилофарингіту в дітей

Abstract

Purpose - to determine the results of the use of bacteria of the genus Bacillus spp. in the form of a spray (Bioplasmix spray for throat) in the treatment of the children with acute tonsillopharyngitis. Materials and methods. An open, randomized, controlled, post-registration study was conducted among 60 children aged 3-17 years diagnosed with acute respiratory viral infection (ARVI), acute tonsillopharyngitis, who were treated in the clinic of pediatric infections of the Bogomolets National Medical University, Kyiv. Children were divided into two groups - main and control. The control group consisted of 30 children who received treatment in accordance with the local protocol for the diagnosis and treatment of acute respiratory viral infections and influenza, and the main group consisted of 30 children who received in addition to the protocol treatment the prophylactic and hygienic agent Bioplasmix throat spray 2-3 injections 3-4 times a day. Bacterial etiology of tonsillopharyngitis was excluded using the McIsaac diagnostic scale. The study involved children with acute viral tonsillopharyngitis, who had 0-2 points on this scale. The results of the pilot observation indicate a positive effect of the drug Bioplasmix Throat Spray on the course of acute viral tonsillopharyngitis in children. This effect was manifested by a reduction in the time of normalization of the main clinical symptoms, such as fever, sore throat and inflammation of the oropharyngeal mucosa. It should be noted that during the observation period, no adverse reactions were registered in patients who used Bioplasmix Throat Spray, which confirms the high safety profile of the drug and indicates its good tolerability. Conclusions. The use of probiotic bacteria Bacillus spp. (Bioplasmix throat spray) helps to reduce the viral load and eliminate the pathogen, destroy bacterial biofilms, antagonistically displace bacteria, in particular staphylococcus, facilitates the course of ARVI and accelerates the recovery of patients without the development of bacterial complications. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.